Simplex Trading
DWTX

Simplex Trading’s Dogwood Therapeutics DWTX Stock Holding History

Simplex Trading’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,172
Closed -$30K – 10677
2022
Q3 		$30K Buy
+3,172
New +$447K ﹤0.01% 7089

Other funds holding DWTX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Simplex Trading's DWTX Position: Q4 2024 in Review

Simplex Trading sold out of Dogwood Therapeutics (DWTX) in Q4 2024, closing a stake of 4 shares.

Simplex Trading first reported a position in DWTX in Q4 2021 and held it in 8 quarters. The position peaked at $30K in Q2 2023. 10 funds tracked by Wall St. Rank hold DWTX as of Q4 2024.

  • Simplex Trading reported no remaining Dogwood Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Simplex Trading sold 4 Dogwood Therapeutics shares in Q4 2024.
  • Simplex Trading first reported a position in Dogwood Therapeutics in Q4 2021 and held it in 8 quarters.
  • Simplex Trading's Dogwood Therapeutics position peaked at $30K in Q2 2023.
  • 10 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q4 2024.

Based on Simplex Trading's 13F filing for Q4 2024, filed 11 Feb 2025.